The Division of Translational Medicine & Chemical Biology has established a fully functional drug discovery organization with the objective to develop anti-cancer drugs all the way from bench to bedside, i.e. from target identification to proof-of-principle in man. Research is focused on development of small-molecule inhibitors of enzymes involved in the repair of DNA damage. When structural information of the target proteins is available this can be used to an advantage to rationally design inhibitors with improved properties, or to perform high-throughput in silico screening to identify new starting points for lead generation. The facilitities available at SNIC will be exploited for structure-based design and virtual screening.